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Radiosurgical, neurosurgical, or no
intervention for cerebral cavernous
malformations: A decision analysis
Leon A Rinkel1 , Rustam Al-Shahi Salman2, Gabriel JE Rinkel3
and Jacoba P Greving4
Abstract
Introduction: We aimed to evaluate the preferred treatment strategy for patients with symptomatic cerebral cavern-
ous malformations (CCM).
Methods: In a decision model, we compared neurosurgical, radiosurgical, and conservative management. A literature
review yielded the risks and outcomes of interventions, intracerebral hemorrhage (ICH), and seizures. Patients with
CCM rated their quality of life to determine utilities. We estimated the expected number of quality-adjusted life years
(QALYs) and the ICH recurrence risk over five years, according to mode of presentation and CCM location (brainstem
vs. other). We performed analyses with a time horizon of five years.
Results: Using the best available data, the expected number of QALYs for brainstem CCM presenting with ICH or focal
neurological deficit was 2.84 (95% confidence interval [CI]: 2.54–3.08) for conservative, 3.01 (95% CI: 2.86–3.16) for neuro-
surgical, and 3.03 (95% CI: 2.88–3.18) for radiosurgical intervention; those for non-brainstem CCM presenting with ICH or
focal neurological deficit were 3.08 (95% CI: 2.85–3.31) for conservative, 3.21 (95% CI: 3.01–3.36) for neurosurgical, and 3.19
(95% CI: 2.98–3.37) for radiosurgical intervention. For CCM presenting with epilepsy, QALYs were 3.09 (95% CI: 3.03–3.16)
for conservative, 3.33 (95% CI: 3.31–3.34) for neurosurgical, and 3.27 (95% CI: 3.24–3.30) for radiosurgical intervention.
Discussion and conclusion: For the initial five years after presentation, our study provides Class III evidence that for
CCM presenting with ICH or focal neurological deficit conservative management is the first option, and for CCM
presenting with epilepsy CCM intervention should be considered. More comparative studies with long-term follow-
up are needed.
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Introduction
Cerebral cavernous malformations (CCM) may present
with intracerebral hemorrhage (ICH), seizures, or focal
neurological deﬁcit (FND) anatomically related to
CCM location or may be incidental ﬁndings during
cerebral imaging for other reasons.1 The untreated clin-
ical course of CCM is mainly determined by their loca-
tion and mode of presentation.2,3
Patients with CCM may be managed conservatively
accepting the risk of future ICH, FND, or seizure;
alternatively, they may be treated with neurosurgical
excision or stereotactic radiosurgery with the chance
of reducing the risk of future ICH or FND but also
with the risk of treatment complications. This risk of
treatment complications is mainly determined by CCM
location.4 Until now, it has not been possible to make
strong recommendations about CCM management,5
because randomized controlled trials have not been
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performed and observational studies have not reliably
identiﬁed dramatic eﬀects of CCM intervention.6
In the absence of such evidence, decision analysis may
inform CCM management by modeling the outcome of
diﬀerent management approaches based on the best
available data.7
We developed a Markov decision model to compare
quality-adjusted life years (QALY) associated with con-
servative management, neurosurgical excision, or stereo-
tactic radiosurgery for symptomatic CCM, according to
their location and mode of presentation.
Methods
Markov model
The model was designed to simulate three patient
cohorts: (1) patients with brainstem CCM presenting
with ICH/FND, (2) patients with non-brainstem
CCM presenting with ICH/FND, and (3) patients pre-
senting with epilepsy. The cohorts diﬀered in the tran-
sition probabilities associated with complications and
outcomes after intervention and the occurrence and
prognosis of ICH or seizures. We did not study inci-
dental/asymptomatic CCM because their mild clinical
course2 seldom creates a dilemma about their manage-
ment.5 We grouped patients with ICH or FND because
their clinical impact seems to be equal,8 and many FND
may be undetected ICH.1 We did not study patients
with a solitary seizure separately, because 94% of the
people presenting with a solitary seizure develop a
second seizure9 and the International League Against
Epilepsy classify people with a CCM and solitary seiz-
ure as having epilepsy.3 The model contained four
mutually exclusive health states: well with treated or
untreated CCM, disabled (after intervention, epilepsy,
ICH, or FND), and death (online Figure e-1).
We estimated the risks of symptomatic ICH and
seizure freedom following conservative management
or intervention and also the risks of death, permanent
disability, or complete recovery after ICH, seizures, or
complications of intervention.
Published estimates of transition probabilities
Using several electronic search strategies, we systemat-
ically reviewed published studies of CCM from the
inception of Medline and Embase to December 2016
(online Table e-2), to identify the best available studies
supplying the relevant probabilities of events and of
transition from one health state to another at each
node of the decision trees. All event probabilities, tran-
sition probabilities, their parameters, distribution, and
references to the studies from which these data were
derived are described in online Table e-2.
We included studies if they reported outcomes strati-
ﬁed by CCM location (brainstem vs. non-brainstem) and
mode of symptomatic presentation (ICH with or without
FND vs. epilepsy) for> 95% of participants with CCM.
If key studies did not report data in these categories, we
contacted corresponding authors for this information. We
selected data from the studies with the least biased design
according to the Centre for Evidence Based Medicine’s
Levels of Evidence (www.cebm.net/wp-content/uploads/
2014/06/CEBM-Levels-of-Evidence-2.1.pdf). If more
than one study fell in the category with the
least biased design, we pooled their results to derive
an overall transition probability. Results of studies
were pooled based on patients’ CCM location and
mode of presentation. Rates were derived in events
per patient-years, based on the number of included
patients and median duration of follow-up in each indi-
vidual study.
Risk of ICH
The risk of ICH from CCM is determined by its
location and mode of presentation.2 We used diﬀerent
ICH recurrence risks according to the type of interven-
tion. We also used diﬀerent outcomes for ICH from
brainstem and non-brainstem CCM. Models allowed
for multiple episodes of ICH and for the decrease in
risk of the ﬁrst recurrent ICH over time during conser-
vative management by using the published estimates.2
For subsequent recurrent ICH, we used the estimate of
the ICH recurrence rate in the model’s ﬁrst cycle and
the median of the published estimates of ICH recur-
rence rate in years 2 to 5 for all subsequent cycles of
the model.
Risk of seizures
We used diﬀerent seizure freedom rates, immediately
following intervention and for the years thereafter, for
the three management strategies. We also estimated the
seizure risk of non-brainstem CCM initially presenting
with ICH/FND.
Risk of complications
We deﬁned complications as transient disability, per-
manent disability, and death following intervention
and estimated their risks according to CCM location,
mode of presentation, and intervention strategy.
Risk of death from other causes
We used age-speciﬁc mortality rates for 30-year-old
persons from Scottish National health tables to esti-
mate the risk of death from other causes.10
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Model assumptions
Probabilities that were not identiﬁed by the literature
search were estimated using reasonable assumptions.
Data from the retrieved articles did not allow us to esti-
mate ICH rates after SRS stratiﬁed by mode of presen-
tation, so we used transition probabilities after
SRS based only on CCM location for non-brainstem
CCM.11 We assigned the same risk of seizure freedom
after SRS and conservative management, because of the
lack of data on seizure freedom after SRS. Due to the
paucity of information on disability after ICH and seiz-
ure caused by CCM, and the lack of a single measure of
disability after these distinct outcomes, we assumed that
patients were disabled after ICH if their modiﬁed
Rankin Scale score was 3. We also assumed that the
outcome after recurrent ICH was the same as after the
ﬁrst ICH and that people with epilepsy who were not
seizure free were disabled until they experienced a year
of seizure freedom. Due to the same paucity of informa-
tion, we modeled that a patient could experience either
an ICH or a seizure within the same year.
Survey of QoL among patients with CCM
We identiﬁed only two studies of quality of life (QoL)
for people with CCM (both after intervention).12,13
Therefore, we designed a survey using SurveyMonkey
(www.surveymonkey.co.uk) and asked the Cavernoma
Alliance UK (CAUK; www.cavernoma.org.uk)
patient support organization to contact patient mem-
bers on 30 November 2016. The survey contained struc-
tured questions to characterize their CCM, clinical
history, and QoL using the ﬁve-level EQ-5D version
of the EuroQol.14 CAUK contacted non-responders
by e-mail once and collected ﬁnal responses on 16
January 2017.
The results provided by CAUK were anonymized,
without the possibility to trace back individual patients.
We summarized responses stratiﬁed by respondents’
CCM location, presentation and management, and cal-
culated each group’s utility value using the EQ-5D-5L
Value Set for England.15 We used the published esti-
mate of population norms for the utility value of the
well health state.16
Health outcomes
We determined the expected number of ICH recur-
rences, along with diﬀerences in QALYs over ﬁve
years. QALYs were calculated by multiplying the time
a person remained in a certain health state by the utility
associated with that particular health state and subse-
quent summing over all health states. Five-year ICH
recurrence risk was estimated from the expected
number of ﬁrst ICH recurrences in the diﬀerent
management arms divided by the total number of simu-
lated persons in these arms.
Statistical analysis
In the Markov model, analyses with a life-time horizon
proved impossible due to the lack of data. We used
cycles of one year and a total time horizon of ﬁve
years. QALYs were calculated over the ﬁve-year time
horizon and are presented as the mean outcomes per
patient. Eﬀectiveness was discounted at 3.5%, as recom-
mended.17 We applied half-cycle corrections to all
models. Signiﬁcance was assumed if there was no over-
lap in the conﬁdence intervals of QALYs between the
diﬀerent strategies. We performed probabilistic sensitiv-
ity analysis using Monte Carlo simulations of 10,000
patients per model, to evaluate the eﬀect of varying the
input parameters over the ranges given in online Table e-
2. We used analysis of covariance methods (ANCOVA)
to assess the contribution to the variance of incremental
QALYs of individual input parameters for all variables.
This allowed us to determine which input parameters
contributed most to the variance of incremental
QALYs in each model. Determining whether variables
for which assumptions had been made had a consider-
able contribution to the variance in QALYs allowed us
to establish the robustness of the model to these assump-
tions. We used SPSS Statistics (version 22.0.0.1, IBM) to
estimate and compare variable frequencies and distribu-
tions, TreeAge (Pro 2017, R1.0. TreeAge Software,
Williamstown, MA) to model outcomes for each deci-
sion tree and perform the sensitivity analyses and R (ver-
sion 3.3.0, package earth) to perform the ANCOVA.
Patient consent and ethical approval
Before designing the survey, we used a decision tool from
the UK Health Research Authority (HRA, https://www.
hra.nhs.uk/approvals-amendments/what-approvals-do-i-
need/) to check whether HRA or ethical approval would
be needed. The UKHRA standards deemed there was no
need for HRA or ethical approval. The survey was
approved and conducted by the Executive Committee
of CAUK. The results provided by CAUK were anon-
ymized, without the possibility to trace back individual
patients. Patients provided informed consent for their
anonymized information to be published in this article
when responding to the survey.
Results
Survey
From the 761 CCM patients invited to complete the
survey, 207 (27%) responded. We excluded eight
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incomplete responses and another 59 because they had
a spinal cavernous malformation or asymptomatic
CCM. We estimated utility values for each model
(Figure 1) according to CCM location and mode of
presentation from subgroups of the included 140
adults with CCM (characteristics described in online
Table e-3) who provided responses.
New episodes of ICH
For conservatively managed patients, the ICH recur-
rence risk was 27.6% (95% CI: 22.3–32.6) for those
with a brainstem and 16.4% (14.3–19.1) for those with
a non-brainstem CCM. For patients who were treated
with radiosurgery or neurosurgery, the conﬁdence inter-
vals for ICH recurrence rate according to location were
overlapping. Recurrence rates were lowest after neuro-
surgical excision (Table 1).
QALYs
For persons presenting with ICH/FND, despite diﬀer-
ences in the risk of recurrent ICH over ﬁve years,
there were no statistically signiﬁcant diﬀerences
between management strategies in QALYs over ﬁve
years, regardless of CCM location (Table 1). For per-
sons presenting with epilepsy, intervention was superior
to conservative management and neurosurgical excision
was superior to radiosurgery.
Sensitivity analyses
The results of the ANCOVA showed that for brainstem
CCM, the case fatality following ICH is the most
important for explaining uncertainty of incremental
QALYs gained with neurosurgical or radiosurgical
intervention compared to conservative management.
The ICH rate in the ﬁrst two years following radiosur-
gery is the most important for explaining uncertainty of
incremental QALYs gained between radiosurgical and
neurosurgical intervention.
For non-brainstem CCM, the case fatality after ICH
and the utility after intervention are for CCM the most
important for explaining uncertainty of incremental
QALYs gained with neurosurgical or radiosurgical
intervention compared to conservative management.
Figure 1. Quality of life (utility values derived from the EQ-5D-5L index score) completed by 140 patients who responded to the
survey, stratified by CCM location, mode of presentation, and receipt of any CCM intervention. The thick horizontal bars indicate
the median. The height of the box corresponds to the difference between the 75th and 25th percentiles (i.e., the interquartile
range [IQR]). Circular outliers are values between 1.5 and 3 IQRs from the end of a box. Asterisked outliers are values >3 IQRs
from the end of a box. There was no statistically significant difference in median utility values between groups (Kruskal–Wallis test
p¼ 0.264). ICH: intracerebral hemorrhage.
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Utility after intervention is the most important for
explaining uncertainty of incremental QALYs gained
between radiosurgical and neurosurgical intervention.
For CCM presenting with epilepsy, utility after con-
servative management and after intervention for CCM
are the most important for explaining uncertainty of
incremental QALYs gained with neurosurgical or
radiosurgical intervention compared to conservative
management. The utility after CCM intervention is
most important for explaining uncertainty of incremen-
tal QALYs gained between radiosurgical and neurosur-
gical intervention.
Discussion
This decision analysis showed that outcomes over ﬁve
years were similar for all strategies for brainstem and
non-brainstem CCM presenting with ICH or FND, des-
pite the decrease in ICH rates after intervention.
Outcomes were better after neurosurgical or radiosurgi-
cal intervention compared to no intervention for CCM
presenting with seizures. Variance in these models’ esti-
mates was most aﬀected by estimates of case fatality
after ICH and the utility value for disability.
This is the ﬁrst decision analysis for the management
of CCM. Our ﬁndings are consistent with the few previ-
ous comparative studies of outcome after CCM
intervention or conservative management, some of
which have found beneﬁts associated with CCM inter-
vention, and others have found harms.4 The better out-
comes associated with intervention in CCM presenting
with seizures we found, concurs with emerging compara-
tive observational studies. Our data show that the gain in
QoL is not only statistically signiﬁcant but also clinical
relevant, with an additional three months of good QoL
gained within the initial ﬁve years after intervention.
Our study has several strengths. We could stratify
our models not only by CCM location and mode
of presentation but also by mode of intervention.
We found some published evidence for most event
rates and transition probabilities to use in our
models. We involved a patient support organization
in this study to obtain utility values for health states
directly from patients, stratiﬁed by their CCM location,
mode of presentation, and intervention. Moreover, we
performed sensitivity analyses to assess which variables
are pivotal in explaining the diﬀerence in QALY’s
between management strategies in the models. The
identiﬁed variables can be subject of further studies to
derive more precise estimates (Table 2). We also
encountered shortcomings in our data retrieval and
model design. Firstly, although our literature search
was extensive and included the best available evidence,
many of the observational studies that provided
Table 1. Five-year outcomes (mean of 2000 iterations in simulated cohorts of 10,000 adults with symptomatic CCM) stratified by
CCM location, mode of presentation, and type of management
Risk of recurrent ICH
over five years, % (95% CI)
QALY over five
years (95% CI)
Brainstem CCM, presenting with ICH/FND
Conservative management 27.6 (22.3–32.6) 2.84 (2.54–3.08)
Neurosurgical excision 3.3 (1.8–6.3) 3.01 (2.86–3.16)
Stereotactic radiosurgery 13.8 (6.0–24.3) 3.03 (2.88–3.18)
Non-brainstem CCM, presenting with ICH/FND
Conservative management 16.4 (14.3–19.1) 3.08 (2.85–3.31)
Neurosurgical excision 3.4 (0.1–9.8) 3.21 (3.01–3.36)
Stereotactic radiosurgery 12.9 (5.2–18.6) 3.19 (2.98–3.37)
Non-brainstem CCM, presenting with epilepsy
Conservative management – 3.09 (3.03–3.16)
Neurosurgical excision – 3.33 (3.31–3.34)
Stereotactic radiosurgery – 3.27 (3.24–3.30)
Note: We derived the confidence intervals for QALYand the risks of recurrent ICH from the Monte Carlo simulations. ICH: intracerebral hemorrhage;
FND: focal neurological deficit; QALY: quality-adjusted life years; CI: confidence interval; CCM: cerebral cavernous malformation.
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estimates of transition probabilities were small, and
some may have been aﬀected by reporting bias, selec-
tion bias, and confounding.6 We were unable to take
other factors than CCM location and mode of presen-
tation, such as age and sex, into account while pooling
the data from studies for several variables, due to a
paucity of description of patient characteristics in sev-
eral studies. We also had to make assumptions about
some individual probabilities because we were unable
to ﬁnd any published estimates of them. As in decision
modeling the outcome of the analysis depends on the
input of data from the literature, the lack of high-qual-
ity data for some variables may aﬀect the results. We
therefore performed probabilistic sensitivity analysis
using Monte Carlo simulations of 10,000 patients per
model. Secondly, we were unable to perform simula-
tions over patients’ entire lifetimes because the risks
of most outcomes from CCM are only available over
ﬁve years’ follow-up, during which there is evidence of
time-dependent variation.2 Thirdly, although signiﬁ-
cance was assumed when there was no overlap in con-
ﬁdence intervals in QALYs between the diﬀerent
management strategies, there might be a signiﬁcant dif-
ference while there is some degree of overlap of the
conﬁdence intervals. Fourthly, we were unable to
account for CCM multiplicity, de novo CCM forma-
tion, spontaneous CCM disappearance, or radio-
graphic sub-type of CCM because existing published
estimates of risks with CCM management have not
been stratiﬁed by these variables. The EQ-5D we used
to determine utility values for the Markov model is not
a disease-speciﬁc, but a generic instrument. Generic
instruments are potentially less responsive to clinically
important changes in health in a speciﬁc patient popu-
lation. Moreover, as we received anonymized data on
the QoL of members of the patient organization
CAUK, we were unable to verify CCM characteristics.
Lastly, we were unable to perform a cost-eﬀectiveness
analysis because of the lack of reliable data on costs
tailored to our models, other than an analysis that
simply calculated economic burden in one country.18
For clinical practice, our data can be used to inform
patients about the eﬀects of the diﬀerent management
strategies for the initial ﬁve years after the CCM has
become symptomatic and to inform patients on the lack
of data for eﬀects after these initial ﬁve years. Because
we were unable to determine a consistently superior
management strategy for CCM presenting with ICH
or FND, we interpret the results of our study as Class
III evidence that for these CCM conservative manage-
ment in general is the ﬁrst option. For CCM presenting
with epilepsy, our data provide Class III evidence that
both CCM interventions are superior to conservative
management which concurs with emerging comparative
observational studies.19 It should be kept in mind, how-
ever, that this conclusion is based on results from ana-
lyses with a ﬁve-year time horizon, and not with a
remaining life-time horizon.
For future research, implications are that several
estimates of outcome – especially QoL – remain to be
Table 2. Study summary
What’s new in this study?
First decision analysis comparing all management strategies for symptomatic CCM
Based on the best available estimates of event rates and probabilities of health states for CCM
We acquired and used disease-specific utility values from patients with CCM
We did not find robust differences between the overall five-year outcomes of intervention vs. conservative management for
CCM
presenting with ICH/FND
Our data suggest that the overall five-year outcome is better after intervention than conservative management for CCM
presenting with epilepsy
Identified uncertainties based on the proportion of model variance accounted for by variables
What uncertainties need to be addressed to reduce uncertainty in future decision analyses on CCMmanagement?
Case fatality and disability after ICH and FND, stratified by CCM location
Outcomes after intervention of non-brainstem CCM presenting with ICH/FND
Long-term (>5 years) risks of ICH and seizure following conservative management and intervention
Quality of life for people with CCM, stratified by management strategy, at standardized time points in relation to presentation/
treatment
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determined. More robust data are required for esti-
mates that were shown to be most important in explain-
ing the variance in QALYs between the diﬀerent
management strategies. More studies comparing man-
agement strategies for CCM are required to test the
hypothesis that intervention is superior to conservative
management in certain sub-groups of patients. Because
of the lack of convincing eﬀects in existing observa-
tional studies and this decision analysis, a randomized
controlled trial would be the ideal study design to deter-
mine the most eﬀective management strategy for CCM
by mode of presentation and location. More data on
long-term seizure risk after conservative management
or intervention are needed for CCM presenting with
seizure(s). More comparative studies for CCM present-
ing with ICH/FND are needed to estimate treatment
eﬀects on QoL, which would be useful as input for
future randomized controlled trials.
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